

II. Symposium of Young Researchers on Pharmaceutical Technology, Biotechnology and Regulatory Science

January 23-24th 2020. Szeged, Hungary

OP-11

DOI: 10.14232/syrptbrs.2020.op11

Curcumin loaded PEGylated nanoemulsions: development and physicochemical characterization towards *in vivo* pharmacokinetic experiments

Jelena Đoković, Snežana Savić

Department of pharmaceutical technology and cosmetology, Faculty of Pharmacy - University of Belgrade

PEGylated nanoemulsions (NEs) can increase target site concentration of the incorporated active by increasing circulation time of the oil droplets [1]. Using experimental design approach best preparation conditions were chosen for further research. Curcumin was used as a model drug and incorporated into formulations selected by experimental design. The aim of this study was to follow the stability of PEGylated and the non-PEGylated NEs and to assess the impact of PEGylated phospholipids' (PEG-PLs) addition on nanoemulsions' long term stability. Additionally, the impact of PEG-PLs on drug release was assessed through *in vitro* drug release studies in order to choose the best candidates for *in vivo* pharmacokinetic study.

NEs were prepared by high pressure homogenization [2]. Nanoemulsions' stability was followed for 12 months by measuring mean droplet size (Z-ave), polydispersity index (PDI) and zeta potential (ZP). Drug release was studied by reverse dialysis bag method.

Initial Z-ave of all NEs (103–106 nm), PDI (< 0.2) and ZP around –40 mV, suggested they are adequate for parenteral application. After 12 months these parameters did not significantly change. During *in vitro* release study the biggest release of curcumin was from the formulation containing 0.3% of PEG5000DPPE (43.38%) vs the lowest with 0.1 % of PEG2000DSPE (25.88%).

This study showed the usefulness of D-optimal factorial design in NEs development. Formulations containing 0.1 % of PEG2000DSPE/PEG5000DPPE were chosen for further step - a pharmacokinetic study.

References

1. Hörmann K. J. Control. Release 223 (2016), 85–98
2. Đorđević S. Int J Pharm, 493 (2015), 40-54

Supervisor: Snežana Savić